GSA Capital Partners LLP Invests $409,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

GSA Capital Partners LLP purchased a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 122,447 shares of the company’s stock, valued at approximately $409,000. GSA Capital Partners LLP owned 0.17% of Trevi Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. American Century Companies Inc. grew its stake in Trevi Therapeutics by 17.1% during the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after purchasing an additional 7,902 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after buying an additional 11,450 shares during the period. Price T Rowe Associates Inc. MD bought a new position in Trevi Therapeutics during the 1st quarter valued at approximately $47,000. Hsbc Holdings PLC purchased a new position in shares of Trevi Therapeutics during the 2nd quarter worth approximately $61,000. Finally, Rhumbline Advisers boosted its stake in Trevi Therapeutics by 44.8% during the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock valued at $224,000 after purchasing an additional 23,263 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on TRVI shares. Raymond James began coverage on Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Friday, November 8th. Leerink Partners initiated coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.43.

Insider Activity

In other news, CEO Jennifer L. Good sold 10,981 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the sale, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. This trade represents a 4.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders have sold 21,595 shares of company stock worth $64,886. 24.37% of the stock is owned by company insiders.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $2.73 on Friday. Trevi Therapeutics, Inc. has a one year low of $0.97 and a one year high of $4.00. The stock has a 50-day moving average price of $3.12 and a 200 day moving average price of $2.91. The company has a market capitalization of $209.86 million, a P/E ratio of -6.30 and a beta of 1.01.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the previous year, the company posted ($0.08) earnings per share. As a group, equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.